The Los Angeles Post
U.S. World Business Lifestyle
Today: April 09, 2025
Today: April 09, 2025

Vertex Pharma misses sales estimates on weak demand for older CF treatments

FILE PHOTO: A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston
April 26, 2024
Reuters - Reuters

(Reuters) - Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments.

The drugmaker recorded a 35.4% fall in sales of its older CF treatments to $209.2 million.

Cystic fibrosis, affecting around 100,000 people globally, is an inherited disorder that causes severe damage to the lungs, digestive system and other organs.

Vertex said it now expects annual sales of about $9.85 billion from its CF treatments, compared with LSEG estimates of $9.86 billion.

Sales of the company's top-selling CF drug Trikafta came in at $2.27 billion in the quarter, compared with estimates of $2.26 billion.

Vertex reported third-quarter total sales of $2.48 billion, missing estimates of $2.50 billion.

Last month, a panel of advisers to the U.S. health regulator said Vertex and its partner CRISPR Therapeutics could assess potential safety risks of their gene therapy for sickle cell disease, a type of blood disorder, after approval.

Analysts expect the therapy, a first-of-its-kind product to reach the U.S. Food and Drug Administration for review, to win the health regulator's nod by Dec. 8.

Vertex anticipates the number of CF patients taking the company's medicines will continue to grow, including through new approvals and reimbursement for treatment of younger patients.

On an adjusted basis, the company earned $4.08 per share in the third quarter. Analysts had expected a profit of $3.97.

(Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar and Shounak Dasgupta)

Related Articles

Scientists genetically engineer mice with thick hair like the extinct woolly mammoth Just like AI, Chinaโ€™s biotech is disrupting the world. Is the US ready? China says rising food demand requires production boost Novartis buys Blackstone's Anthos for up to $3.1 billion
Share This

Popular

Business|Political|US

US appeals court sides with Trump, clears way to fire thousands of federal workers

US appeals court sides with Trump, clears way to fire thousands of federal workers
Americas|Business|Economy|Political|US

Chile sees positive twist to any Trump tariffs on copper

Chile sees positive twist to any Trump tariffs on copper
Business|Economy|Finance|Political|World

WTO says trade between US, China could decrease by as much as 80%

WTO says trade between US, China could decrease by as much as 80%
Business|Economy|Political|US

Trump not seeking to re-invigorate US-Russia trade with lack of tariffs, Greer says

Trump not seeking to re-invigorate US-Russia trade with lack of tariffs, Greer says

Health

Business|Economy|Health|Science|Technology

PacBio to cut jobs, lower spending over NIH funding cuts and tariffs

PacBio to cut jobs, lower spending over NIH funding cuts and tariffs
Health|Lifestyle|US

Oklahoma City bombing survivor reflects on life nearly 30 years later

Oklahoma City bombing survivor reflects on life nearly 30 years later
Health|Sports|US

Maryland men to run 100 miles to Ocean City to raise money for Parkinson's disease

Maryland men to run 100 miles to Ocean City to raise money for Parkinson's disease
Food|Health|MidEast|Political|World

Six weeks since Israel imposed total Gaza blockade, last food is running out

Six weeks since Israel imposed total Gaza blockade, last food is running out

Access this article for free.

Already have an account? Sign In